ICCPP-GROUP
9.5.2023 13:08:32 CEST | Business Wire | Press release
With the global prevalence of disposable e-cigarettes, there are growing concerns about the environmental problems caused. As one of key influencers of electronic atomization technology companies, as well as the parent company of VOOPOO, ICCPP Group takes these problems seriously and its ODM+ business has creatively developed world’s 1st new dual environmentally-friendly disposable vape solutions, named "Cyclo" series, which combines the concept of detachable and biodegradable, ahead of the industry in advance to achieve user portability and recyclability, will be grandly unveiled at the Vaper Expo UK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005592/en/
The "Cyclo" eco-friendly vape solutions of ICCPP ODM+ (Photo: Business Wire)
Patented PLA Material: The Key to Make Stable Biodegradability Reality The "Cyclo" series are made with our exclusive and patented PLA material, a biodegradable material that is made from starch raw materials proposed from corn, a renewable plant resources, and which can be degraded into carbon dioxide and water in 3-6 months after being recycled and landfilled in the soil, making it a more environmentally friendly material.
In addition, ICCPP has gone through thousands of trials and tests and created a unique internal structure and process to further enhance the stability of unique PLA material, making it maintain its initial strength after thousands of drop and impact tests, to greatly improve the stability and safety of PLA e-cigarette sticks, without destroying the original biodegradable advantages of the material.
Leadless and Modular Design: Making Detachability A Reality
ICCPP’s commitment to environmental sustainability goes much further than just material selection.
We have implemented a wide range of environmentally-friendly design features, including no-soldering lead-free design and pre-automated modular assembly. These design features mean that "Cyclo" vape solutions can be easily disassembled for recycling or disposal, minimizing the environmental impact of manufacturing and using processes.
Multiple Options for Atomization Coils: The Addition of Environmental Concepts
ICCPP’s commitment to environmental sustainability does not end with the product itself. We have also advanced atomization coil technology into "Cyclo" series, resulting in a longer lifespan, less material waste, and a more stable and pure taste for vapers.
The atomization coil technology in the "Cyclo" vape solutions includes the mesh coil technology and the Gene Tree ceramic coil technology. On one hand, our mesh coil technology combines different resistivity application scenarios with a unique multi-layer distribution structure to precisely control the power at a single point and precisely calculate the heat field coverage at a single point to so that the heat is evenly distributed, resulting in a stable, perfect and pure taste.
On the other hand, the Gene Tree ceramic coil technology uses the exclusive powder-free environmental-friendly technology process, nano-microcrystalline ceramic material fired at 3000°, and a multi-layer A+ grade oil guide and oil lock aperture structure to provide more stable and uniform heating. This unique combination of technologies ensures that "Cyclo" e-cigarettes solutions provide customers with more puffs, purer tastes, greater flavor consistency and a superior vaping experience, as well as less environmental concerns .
The Origin of "Cyclo": The Commitment of ICCPP to the Environment and Society
In view of these, we name the electronic cigarettes solutions "Cyclo", representing our dedication to creating a closed-loop, circular product cycle that is both environmentally-friendly and sustainable. Also,the slogan of “Cyclo” is “Cycle of all things", and it reflects our dedications and determination to promoting environmental sustainability in all areas of our business.
In conclusion, the "Cyclo" series of e-cigarettes are the perfect choice for those who want an environmentally-friendly and sustainable vaping experience. With biodegradable materials, recyclable design features, cutting-edge atomization coil technology, as well as our commitment to environmental responsibility, we invite you to join us in the journey towards a more sustainable future.
Of course, apart from “Cyclo” eco-friendly products, ICCPP ODM+ brings dozens of vapes including refillable pods and disposable pods for UK e-cigarette enthusiasts and industry experts that meet local market flavor and puff preferences and also obey local regulations. Welcome to E10 booth at NEC of Birmingham and we look forward to seeing you on May 12th-14th 2023.
1)About ICCPP ODM+:
ICCPP ODM+ is an innovative ODM strategic cooperation model created by ICCPP Group in 2022, which puts forward the business proposition of “branding first, product integrating technology and marketing”.
Through all-round innovations and breakthroughs in technology+, product+, flavor+, quality+, compliance+ and marketing+, ICCPP ODM+ provides more premium vape solutions and services for customers' brands, so as to bring a healthier and happier electronic atomization life to global consumers and to achieve long-term development of both customers' brands and ICCPP ODM.
2)About ICCPP Group:
ICCPP Group, the parent company of VOOPOO, is a comprehensive electronic atomization ecological group with the whole industrial chain layout. It is rapidly developing with a new business model of matrix, internationalization and platform, integrating technology R&D, product design, intelligent manufacturing, brand operation and supply chain management.
With 9 years of full industry chain layout and global localization, ICCPP's electronic atomization products and solutions have been applied in more than 70 countries worldwide, covering 100,000 offline outlets and more than 36 million consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005592/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
